Trial Profile
An open-label, long-term, multi-center, intrathecal Ziconotide (PRIALT) effectiveness and safety trial (ZEST) in patients with chronic severe pain
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Feb 2009
Price :
$35
*
At a glance
- Drugs Ziconotide (Primary)
- Indications Pain
- Focus Therapeutic Use
- Acronyms ZEST
- 18 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2005 New trial record.